Multaq and Atacand drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Multaq (dronedarone hydrochloride) and Atacand (candesartan cilexetil). Common drug interactions include pulmonary hypertension among females and dyspnoea among males.

The phase IV clinical study analyzes what interactions people have when they take Multaq and Atacand. It is created by eHealthMe based on reports of 66 people who take the same drugs from the FDA, and is updated regularly.

What is Multaq?

Multaq has active ingredients of dronedarone hydrochloride. It is often used in atrial fibrillation/flutter. eHealthMe is studying from 11,053 Multaq users. Check the latest studies of Multaq.

What is Atacand?

Atacand has active ingredients of candesartan cilexetil. It is often used in high blood pressure. eHealthMe is studying from 22,473 Atacand users. Check the latest studies of Atacand.

On Aug, 02, 2026

66 people who take Multaq and Atacand together, and have interactions are studied.

What are the common drug interactions of Multaq and Atacand, by gender? *:

female:

Pulmonary hypertension (increase in blood pressure in the lung artery)
Abdominal pain
Blood pressure decreased
Fatigue (feeling of tiredness)
Pruritus (severe itching of the skin)
Alanine aminotransferase increased
Aspartate aminotransferase increased
Bladder cancer
Drug hypersensitivity
Gamma-glutamyltransferase increased

male:

Dyspnoea (difficult or laboured respiration)
Renal failure (kidney dysfunction)
Hepatic encephalopathy (spectrum of neuropsychiatric abnormalities in patients with liver failure)
Abnormal behaviour
Alanine aminotransferase increased
Atrophic vulvovaginitis (inflammation of the vulva)
Blood pressure decreased
Bradycardia (abnormally slow heart action)
Cheilitis (infection of lips)
Completed suicide (act of taking one's own life)

What are the common drug interactions of Multaq and Atacand, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

Blood pressure decreased
Diarrhoea
Hypoglycaemia (deficiency of glucose in the bloodstream)
International normalised ratio decreased
Somnolence (a state of near-sleep, a strong desire for sleep)

50-59:

Hyperthyroidism (over activity of the thyroid gland)
Interstitial lung disease
Nausea (feeling of having an urge to vomit)
Pyrexia (fever)
Restrictive pulmonary disease (reduction in total lung capacity)
Hepatitis toxic
Blood bilirubin increased
Cerebral haemorrhage (bleeding within the brain)
Chest pain
Cough

60+:

Renal failure (kidney dysfunction)
Diarrhoea
Azotaemia (excess of urea or other nitrogenous compounds in the blood)
Decreased appetite
Bradycardia (abnormally slow heart action)
Gait disturbance
Hepatocellular injury (liver injury)
Jaundice (a yellowish pigmentation of the skin, the conjunctival membranes)
Alanine aminotransferase increased
Cholestasis (a condition where bile cannot flow from the liver to the duodenum)

What are the existing conditions these people have? *

Arrhythmias (irregular heartbeat): 5 people, 7.58%

* Approximation only. Some reports may have incomplete information.

Do you take Multaq and Atacand?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously